Clinical trials: Ledderhose Disease
Ledderhose Disease
Ledderhose Disease - Long Term Effects of Radiotherapy Treatment. LedRad LTE - Study
The aim of the LedRad LTE study is to determine the current complaints, late side effects and satisfaction of patients who were treated with radiotherapy for Ledderhose disease at least two years ago.
- Trial name
- NCT04229147
- Testing
- Radiotherapy
- Where
- Netherlands
- Volunteers
- 68 people
- Sponsor
- University Medical Center Groningen
Plantar Fibromatosis
Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.
- Trial name
- NCT05152173
- Testing
- EN3835
- Where
- 43 sites in United States
- Volunteers
- 176 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Ledderhose Disease
Ledderhose Disease: Radiotherapy or Not?
The aim of the LedRad trial is to determine the efficacy and durability of radiotherapy as treatment for patients with Ledderhose disease and to compare this to the natural course of Ledderhose disease.
- Trial name
- LedRad (NCT03507010)
- Testing
- Radiotherapy
- Where
- Netherlands
- Volunteers
- 84 people
- Sponsor
- University Medical Center Groningen
Plantar Fibromatosis, Ledderhose Disease
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
- Trial name
- STRIDE (NCT06151197)
- Testing
- EN3835
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 436 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Plantar Fibromatosis
Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Assess the long-term safety and efficacy of EN3835 in participants who have participated in a parent placebo-controlled study of EN3835 (EN3835-222, NCT05152173) and assess the efficacy and safety of EN3835 in the treatment and…
- Trial name
- NCT05254457
- Testing
- EN3835
- Where
- 27 sites in United States
- Volunteers
- 145 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company